For the quarter ending 2025-09-30, AQST made $12,807K in revenue. -$15,446K in net income. Net profit margin of -120.61%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 12,807 | 10,003 | 8,720 | 13,542 |
| Manufacture and supply | 4,506 | 4,561 | 3,652 | 4,437 |
| Research and development | 4,530 | 4,105 | 5,361 | 5,269 |
| Selling, general and administrative | 15,250 | 12,705 | 19,072 | 12,126 |
| Total costs and expenses | 24,286 | 21,371 | 28,085 | 21,832 |
| Loss from operations | -11,479 | -11,368 | -19,365 | -8,290 |
| Interest expense | 2,779 | 2,781 | 2,782 | 2,780 |
| Interest expense related to royalty obligations | 1,433 | 1,434 | 1,437 | 1,359 |
| Interest expense related to the sale of future revenue | 61 | 61 | 59 | 59 |
| Interest income and other income, net | 306 | 2,096 | 713 | 979 |
| Net loss before income taxes | -15,446 | -13,548 | -22,930 | -11,509 |
| Net loss | -15,446 | -13,548 | -22,930 | -11,509 |
| Comprehensive loss | -15,446 | -13,548 | -22,930 | -11,509 |
| Basic (in dollars per share) | -0.14 | -0.14 | -0.24 | -0.13 |
| Basic (in shares) | 110,584,371 | 99,326,701 | 95,497,056 | 91,082,081 |
| Diluted (in dollars per share) | -0.14 | -0.14 | -0.24 | -0.13 |
| Diluted (in shares) | 110,584,371 | 99,326,701 | 95,497,056 | 91,082,081 |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)